These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9633849)

  • 1. Update on the role of radiotherapy in ovarian cancer.
    Lanciano R; Reddy S; Corn B; Randall M
    Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
    Powell JL; Kirchner AB
    J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
    [No Abstract]   [Full Text] [Related]  

  • 3. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
    Wilkinson RH
    J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intraperitoneal irradiation in limited epithelial neoplasms of the ovary. Review of the literature].
    Wolff JP; Burini GA
    Minerva Ginecol; 1985; 37(7-8):407-13. PubMed ID: 3906441
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
    Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
    J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
    Tulchinsky M; Eggli DF
    Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
    Walton LA; Yadusky A; Rubinstein L
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):939-44. PubMed ID: 2022522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
    Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
    J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
    Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
    Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of elderly patients with gynecologic cancer.
    McGowan L
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):53-6. PubMed ID: 7742517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
    Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
    Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian carcinoma: adjuvant treatment with P-32.
    Reddy S; Sutton GP; Stehman FB; Hornback NB; Ehrlich CE
    Radiology; 1987 Oct; 165(1):275-8. PubMed ID: 3628782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites.
    Balink H; Sijmons EA; Zonnenberg BA; De Klerk JM
    Clin Nucl Med; 2003 Jul; 28(7):545-7. PubMed ID: 12819405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
    Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
    Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary cytoreduction in epithelial ovarian cancer.
    Morgan MA; Rubin SC
    Crit Rev Oncol Hematol; 1995 Jan; 18(1):1-8. PubMed ID: 7695822
    [No Abstract]   [Full Text] [Related]  

  • 16. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
    Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y
    J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
    McGowan L
    Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current aspects of adjuvant therapy of early stage ovarian cancer.
    McGuire WP
    Zentralbl Gynakol; 1998; 120(3):93-7. PubMed ID: 9556898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
    Soper JT; Berchuck A; Clarke-Pearson DL
    Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
    Sharma SC; Osborne RP; Jose B; Carlson JA
    Health Phys; 1984 Sep; 47(3):452-4. PubMed ID: 6500947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.